FKBP12 Protein - ACROBiosystems

Home
Products

products by category

Recombinant proteins
GMP Grade CytokinesNew Fc receptor proteins FcRn Proteins IgG Fc Proteins (Isotype Control) CGT development solutions New Targets of CAR-T cell therapy New Generation Tools for CAR DetectionStar Staining FDA DMF filed proteins Multi-pass TpsHot Immune checkpoint proteins ADC targets BsAb targets TME pathway targets CytokinesHot Enzymes Llama IgG Fc fusion protein Biosimilar drug targets Biomarkers & CD antigens All recombinant proteins

Antibodies
Anti-idiotypic antibody Anti-FMC63 mAb Neutralizing antibodies IgG Isotype Controls: Anti-DNP Antibodies
Support on research about infectious diseases Hot
Core reagents for infectious disease researchNew SARS-CoV-2 related products Reagents for vaccine development SARS-CoV-2 mutant products SARS-CoV-2 related kits Reagents for diagnostic development
Kits/Beads
Pre-coupling magnetic beads Inhinitor screening kits ELISA Assay Kits for Quantitative analysis of therapeutic antibodies in serum

Featured products

Pre-labeled proteins
New Generation Tools for CAR DetectionStar Staining Biotinylated protein collection FITC & PE labeled proteins
Full-length multi-pass TpsHot
Multi-pass Tps Claudin 18.2 GPCRs CD20 proteins
Proteins for Neuroscience
Proteins for Neuroscience New Pre-formed Fibrils (PFFs) New
Cytokines
ActiveMax Cytokines Hot Promising Therapeutic Targets Hot
Streptavidin (SA) series Products
SA, SA Coated Plates, SA Magnetic Beads New
Isotype Controls
Anti-DNP AntibodiesHot IgG Fc ProteinsHot Serum AlbuminHot

Hot targets
CD19 BCMA CD3 proteins IL-2 and IL-2 receptor proteins IL-6 and IL-6 receptor proteins Claudin 18.2 GPCRs CD20 proteins CD39/CD73 proteins B7 families TNFSF proteins VEGF proteins PD1 proteins TIGIT Siglec-15 proteins Integrin CD24&siglec-10

Brands
FLAG Star Staining ViruStop Aneuro ComboX ActiveMax GENPower
Services

Innovation Lab
SPR /BLI analytical serviceNew Enzyme-Linked Immunosorbent Assay (ELISA) Service New Meso Scale Discovery (MSD) ServiceNew Anti-Idiotypic Antibody Development ServiceNew Pseudovirus Neutralization Assay ServiceNew MHC Class I Complex Custom ServiceNew

Licensing Opportunities
Target 4-1BB monoclonal antibody New PD-1/CD80 bispecific antibodyNew Antagonizing TSP1/CD36 Polypeptide Blocking the activation of TGF-β1New Anti-PD-L1 / TIGIT bispecific antibodyNew TIGIT-Fc proteinNew Novel small molecule drug for cancer cachexiaNew
Supports

How to Order Shipping & Payments Global Distributors Testimonials FAQs Download COA
Applications

The Process of How SARS-CoV-2 Infects the Host Quantitative Analysis of mAb in Serum Evaluation of CAR Expression Claudin18.2-VLP：designed for CAR detection SPR & BLI：Binding activity assay SEC-MALS: Aggregation state and purity
News

News Insights Promotions Exhibitions
Resources

Download Brochures Download E-resources Download COA
ACROBiosystems

About Us Join Us Contact Us

FKBP12

Brief Information

Name:FK506-binding protein 1A
Target Synonym:Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A,FK506-Binding Protein, T-Cell, 12-KD,FK506-Binding Protein 1A (12kD),Protein Kinase C Inhibitor 2,FK506-Binding Protein 12,FK506 Binding Protein12,FK506-Binding Protein 1,FKBP12-Exip3,Calstabin 1,PPIASE,PKC12,PKCI2,Tacrolimus Binding Protein 1A,FKBP12C,FK506 Binding Protein 1A, 12kDa,12 KDa FK506-Binding Protein,Immunophilin FKBP12,12 KDa FKBP,Rotamase,FKBP Prolyl Isomerase 1A,FKBP1,FKBP12,FKBP-12,PPIase FKBP1A,FK506-binding protein 1A,Calstabin-1,FKBP-

Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved


FKA-H5122	Human	Human FKBP12 / FKBP1A Protein, His Tag

Cat. No.

Species

Product Description

Structure

Purity

Feature

FKA-H5122

Human

Human FKBP12 / FKBP1A Protein, His Tag

Synonym Name

FKBP1A,FKBP1,Calstabin-1,FKBP12,Rotamase,PKC12,PPIASE

Background

Peptidyl-prolyl cis-trans isomerase FKBP1A, a member of the FKBP-type PPIase family and FKBP1 subfamily, is also known as FK506-binding protein 1A, immunophilin FKBP12 and 12 kDa FK506-binding protein, which contains one PPIase FKBP-type domain. FKBP1A is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 (tacrolimus) and rapamycin (sirolimus).FKBP1A interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. FKBP1A can also interact with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine receptor. Furthermore, FKBP1A can recruite SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal.

Clinical and Translational Updates

Public Drug Information

Name	Research Code	Research Phase	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indications	Clinical Trials
Tacrolimus Hydrate	FK-506MR; FK-506E; FK-506; MR-4; RTU-007; LCP-Tacro; FR-900506; L-679934	Approved	Astellas Pharma Inc	Protopy, Graceptor (as hydrate), Protopic, Prograf (as hydrate), Hecoria (as hydrate), Hexal, Envarsus XR, Talymus, 普乐可复, Advagraf, Envarsus, Modigraf, Astagraf XL, TacroBell	United States	Rejection of lung transplantation	Astellas Pharma Inc	1993-01-01	Infertility, Female; Nephrosis, Lipoid; Lymphedema; Conjunctivitis; Psoriasis; Amputation, Traumatic; Conjunctivitis, Allergic; Surgical Wound Infection; Asthma; Pigmentation Disorders; Colitis, Ulcerative; Rejection in heart transplantation; Nephrotic Syndrome; Brain Death; Wounds and Injuries; Renal Insufficiency, Chronic; Keratoconjunctivitis; Coronary Restenosis; Dermatitis, Atopic; Vitiligo; Peripheral Nerve Injuries; Encephalitis; Crohn Disease; Edema; Kidney Failure, Chronic; Dermatomyositis; Myasthenia Gravis; Liver Failure; Reperfusion Injury; Medication Adherence; Polymyositis; Breast Cancer Lymphedema; Genital Diseases, Male; Bone marrow transplant rejection; Glomerulonephritis, IGA; Rejection of liver transplantation; Keratoplasty rejection; Rejection of renal transplantation; Rejection of lung transplantation; Cystitis; Primary Graft Dysfunction; Renal Insufficiency; Lupus Erythematosus, Cutaneous; Kidney Diseases; Arthritis, Rheumatoid; Graft vs Host Disease; Rejection of organ transplantation;	Details

Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
Rimiducid	AP-1903	Phase 2 Clinical	Ariad Pharmaceuticals Inc	Carcinoma, Acinar Cell; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Uveal melanoma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Carcinoma, Adenoid Cystic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Anemia, Aplastic; Prostatic Neoplasms; Osteopetrosis; Metabolic Diseases; Breast Neoplasms; Colorectal Neoplasms; Immune System Diseases; Carcinoma, Mucoepidermoid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Pancreatic Ductal; Lymphohistiocytosis, Hemophagocytic; Urogenital Neoplasms; Leukemia, Biphenotypic, Acute; Anemia, Sickle Cell; Congenital Bone Marrow Failure Syndromes; Prostatic Diseases; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell; Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia; Primary Immunodeficiency Diseases; Ovarian Neoplasms; Leukemia, Lymphoid; Immunoproliferative Disorders; Lymphatic Diseases; Thalassemia; Stomach Neoplasms; Carcinoma, Renal Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positiv	Details